skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle

Review

(2286) Views  (938) Full article downloads

Authors: Andreas Rank, Oliver Weigert, Helmut Ostermann

Published Date May 2010 Volume 2010:4 Pages 139 - 145
DOI: http://dx.doi.org/10.2147/BTT.S3436

Andreas Rank, Oliver Weigert, Helmut Ostermann

Medizinische Klinik III – Grosshadern, Klinikum der Ludwig Maximilians-Universitaet Munich, Munich, Germany

Abstract: Traditionally, anti-platelet autoantibodies accelerating platelet clearance from the peripheral circulation have been recognized as the primary pathopysiological mechanism in chronic immune thrombocytopenia (ITP). Recently, increasing evidence supports the co-existence of insufficient megakaryopoiesis. Inadequate low thrombopoietin (TPO) levels are associated with insufficient proliferation and differentiation of megakaryocytes, decreased proplatelet formation, and subsequent platelet release. Recently two novel activators of TPO receptors have been made available: romiplostim and eltrombopag. In several phase III studies, both agents demonstrated increase of platelet counts in about 80% of chronic ITP patients within 2 to 3 weeks. These agents substantially broaden the therapeutic options for patients with chronic ITP although long-term results are still pending. This review will provide an update on the current conception of underlying mechanisms in ITP and novel, pathophysiologically based treatment options.

Keywords: immune thrombocytopenia, romiplostim, eltrombopag, megakaryopoiesis








Readers of this article also read:

Therapeutic vaccines for malignant brain tumors
Safety of etanercept in elderly subjects with rheumatoid arthritis
Hepatitis B virus and Homo sapiens proteomewide analysis: A profusion of viral peptide overlaps in neuron-specific human proteins
Palliative treatment of malignant ascites: profile of catumaxomab
Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
Managing idiopathic short stature: role of somatropin (rDNA origin) for injection
Use of clofarabine for acute childhood leukemia
New and emerging treatment approaches to lupus
Gut microbiota: next frontier in understanding human health and development of biotherapeutics
Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University

  • Journal Indexing

    See where all the Dove Press journals are indexed